logo

For the Inventor, By the Inventor

Commack, NY, United States of America

An-Hu Li

This inventor holds 26 USPTO granted patents and 6 published patent applications and 4 EPO patents, primarily in Cancer Therapeutics. Top assignees: Osi Pharmaceuticals, Inc., Angion Biomedica Corporation, Other. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: An-Hu Li. Retrieved from https://idiyas.com/inventor/an-hu-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 34.6

 

Average Co-Inventor Count = 6.9

ph-index = 5

Forward Citations = 110(Granted Patents)


Location History:

  • Bay Shore, NY (US) (2005 - 2009)
  • Farmingdale, NY (US) (2008 - 2010)
  • Commack, NY (US) (2010 - 2023)

Company Filing History:

goldMedal21 out of 118 
 
Osi Pharmaceuticals, Inc.
 patents
silverMedal3 out of 26 
 
Angion Biomedica Corporation
 patents
bronzeMedal2 out of 834,570 
Other
 patents

Years Active: 2005-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Rho-associated Kinase
Heterocycles
Kinase Inhibitors
Pyrimidine Compounds
Pyridines
Pyrazines
Bicyclic Compounds
Cancer Treatment
Thiophene Compounds
Fused Bicyclic
Pteridinones
C-Kit Inhibitors
26 patents (USPTO):Explore Patents
1. 11542256 - Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors (2023-01-03),
2. 11370783 - Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole (2022-06-28),
3. 10875849 - Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole (2020-12-29),
4. 9351974 - Substituted pteridinones for the treatment of cancer (2016-05-31),
5. 9096624 - Amino pyrimidine anticancer compounds (2015-08-04),
6. 8735405 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-05-27),
7. 8653268 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-02-18),
8. 8592448 - Substituted pyrrolo[2,3-b]-pyridines and -pyrazines (2013-11-26),
9. 8445510 - Fused bicyclic kinase inhibitors (2013-05-21),
10. 8399433 - Amino pyrimidine anticancer compounds (2013-03-19),
11. 8378104 - 7-aminofuropyridine derivatives (2013-02-19),
12. 8367826 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2013-02-05),
13. 8101613 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2012-01-24),
14. 8022206 - Furo[3,2-C]pyridines (2011-09-20),
15. 7829717 - (Arylamidoaryl)squaramide compounds (2010-11-09),

Title: An-Hu Li: Innovations in Pharmaceutical Compounds

Introduction

An-Hu Li, based in Commack, NY, is a prominent inventor with an impressive portfolio of 26 patents. His work primarily revolves around the development of innovative pharmaceutical compounds and treatments that address various health conditions.

Latest Patents

Among his latest contributions, An-Hu Li has introduced significant patents, including a groundbreaking invention related to vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors. This invention provides compounds with specific formulas and pharmaceutically acceptable salts, aimed at treating conditions where inhibiting ROCK1, ROCK2, or both has therapeutic benefits. Another notable patent involves solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, where he has detailed the compositions and methods for effective usage.

Career Highlights

An-Hu Li has made noteworthy strides in his career, contributing to renowned companies such as Osi Pharmaceuticals and Angion Biomedica Corporation. His expertise in pharmaceutical innovation has played a key role in advancing treatment methodologies in the industry.

Collaborations

Throughout his career, An-Hu Li has collaborated with talented professionals, including Andrew Philip Crew and Hanqing Dong. These partnerships have enhanced the scope of his research and amplified the impact of his innovative endeavors.

Conclusion

An-Hu Li exemplifies a dedicated inventor whose work continues to shape the pharmaceutical landscape. With his extensive patent portfolio and collaborations, he significantly contributes to the development of effective therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…